A phase I pharmacokinetic study of ST1571 [imatinib] in patients with advanced malignancies and varying levels of liver dysfunction

Trial Profile

A phase I pharmacokinetic study of ST1571 [imatinib] in patients with advanced malignancies and varying levels of liver dysfunction

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Haematological malignancies; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top